RJFSA
CRL icon

Raymond James Financial Services Advisors’s Charles River Laboratories CRL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.41M Sell
7,138
-47
-0.7% -$9.77K ﹤0.01% 1935
2024
Q2 		$1.48M Buy
7,185
+1,677
+30% +$380K ﹤0.01% 1845
2024
Q1 		$1.49M Buy
5,508
+2,568
+87% +$613K ﹤0.01% 1816
2023
Q4 		$695K Sell
2,940
-31,134
-91% -$6.12M ﹤0.01% 2202
2023
Q3 		$6.68M Sell
34,074
-715
-2% -$147K 0.01% 876
2023
Q2 		$7.31M Sell
34,789
-4,047
-10% -$805K 0.01% 841
2023
Q1 		$7.84M Buy
38,836
+37,058
+2,084% +$8.4M 0.01% 795
2022
Q4 		$387K Buy
1,778
+107
+6% +$23.4K ﹤0.01% 2413
2022
Q3 		$329K Sell
1,671
-318
-16% -$68.6K ﹤0.01% 2516
2022
Q2 		$426K Sell
1,989
-1,702
-46% -$416K ﹤0.01% 2375
2022
Q1 		$1.05M Sell
3,691
-2,168
-37% -$669K ﹤0.01% 1918
2021
Q4 		$2.21M Sell
5,859
-3,966
-40% -$1.54M ﹤0.01% 1469
2021
Q3 		$4.05M Buy
9,825
+3,543
+56% +$1.47M 0.01% 1085
2021
Q2 		$2.32M Buy
6,282
+3,799
+153% +$1.27M ﹤0.01% 1383
2021
Q1 		$720K Sell
2,483
-108
-4% -$30K ﹤0.01% 2067
2020
Q4 		$647K Sell
2,591
-5,536
-68% -$1.32M ﹤0.01% 1980
2020
Q3 		$1.84M Buy
8,127
+1,034
+15% +$215K 0.01% 1217
2020
Q2 		$1.24M Buy
+7,093
New +$1.13M ﹤0.01% 1359
2020
Q1 		– Sell
-5,003
Closed -$764K – 2476
2019
Q4 		$764K Buy
5,003
+1,771
+55% +$245K ﹤0.01% 1700
2019
Q3 		$428K Sell
3,232
-2,755
-46% -$369K ﹤0.01% 2006
2019
Q2 		$850K Buy
5,987
+230
+4% +$31.2K ﹤0.01% 1590
2019
Q1 		$836K Sell
5,757
-693
-11% -$91K ﹤0.01% 1556
2018
Q4 		$730K Sell
6,450
-135
-2% -$16.9K ﹤0.01% 1435
2018
Q3 		$886K Buy
6,585
+3,533
+116% +$436K ﹤0.01% 1537
2018
Q2 		$343K Buy
3,052
+191
+7% +$20.6K ﹤0.01% 2139
2018
Q1 		$305K Hold
2,861
– – ﹤0.01% 2020
2017
Q4 		$313K Buy
+2,861
New +$311K ﹤0.01% 1996

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Raymond James Financial Services Advisors's CRL Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Charles River Laboratories (CRL) stake by 0.65% in Q3 2024, selling an estimated $9.77K and leaving 7,138 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Raymond James Financial Services Advisors first reported a position in CRL in Q4 2017 and has held it in 27 quarters since. The position peaked at $7.84M in Q1 2023. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Raymond James Financial Services Advisors held 7,138 shares of Charles River Laboratories worth $1.41M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 47 Charles River Laboratories shares in Q3 2024, an estimated $9.77K.
  • Charles River Laboratories made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1935 holding.
  • Raymond James Financial Services Advisors first reported a position in Charles River Laboratories in Q4 2017 and has held it in 27 quarters since.
  • Raymond James Financial Services Advisors's Charles River Laboratories position peaked at $7.84M in Q1 2023.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.